Invesaro

Stocks SION Financial statements

Financial statements

Sionna Therapeutics, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Sionna Therapeutics, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2025FY2025
Research and development57.360.3
General and administrative13.328.7
Operating expenses70.689
Operating income-70.6-89
Interest income8.1713.3
Other non-operating income8.8713.7
Income tax00
Net income-61.7-75.3
EBITDA-69.9-88.3
EPS, basic-15.99-1.88
EPS, diluted-15.99-1.88
Shares, basic (weighted)3.8640
Shares, diluted (weighted)3.8640

Balance sheet

FY2025FY2025
Cash and equivalents37.858.5
Other current assets3.465.54
Total current assets151241
Property, plant and equipment2.472.23
Lease right-of-use assets7.836.93
Other non-current assets2.990
Total assets186326
Accrued liabilities8.169.67
Total current liabilities10.411.7
Lease liabilities8.687.41
Total liabilities19.119.1
Paid-in capital17563
Retained earnings-181-256
Other comprehensive income0.370.54
Shareholders' equity-164307
Total equity-164307
Total liabilities and equity186326
Shares outstanding4.7244.7

Cash flow statement

FY2025FY2025
Net income-61.7-75.3
Depreciation and amortization0.670.65
Stock-based compensation3.7112.1
Change in payables0.47-0.42
Cash from operations-52.8-66.3
Capital expenditures-0.03-0.38
Purchases of investments-183-325
Sales and maturities of investments56207
Cash from investing-127-119
Stock issued0.143.64
Cash from financing179206
Net change in cash-0.7320.7
Free cash flow-52.8-66.7

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.23 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Return on equity (ROE)-36.6%Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)-34.4%Net income / average total assets.
Return on invested capital (ROIC)-42.7%Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.

Growth

MetricValueHow it is calculated
Total assets growth, 1y75.5%Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y935.6%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio20.0xCurrent assets / current liabilities.
Quick ratio5.87x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio5.87x(Cash + short-term investments) / current liabilities.
Liabilities / assets6.2%Total liabilities / total assets.
Working capital$205.3MCurrent assets - current liabilities.
Tangible book value$265.8MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted-$2.16Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share-$1.69Free cash flow / diluted weighted shares.
Operating cash flow per share-$1.68Cash from operations / diluted weighted shares.
Book value per share$5.88Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share$5.88Tangible book value / shares outstanding.
Cash per share$1.40(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$236.5MShare price x shares outstanding.
Enterprise value$173.1MMarket cap + total debt - cash - short-term investments.
P/B0.89xMarket cap / shareholders' equity. Only when equity is positive.
Price / tangible book0.89xMarket cap / tangible book value, when positive.
FCF yield-32.2%Free cash flow / market cap.
Earnings yield-41.2%Net income / market cap (the inverse of P/E).
Was Sionna Therapeutics, Inc. profitable in fiscal 2025?

No. It reported a net loss of $75.3M.

How much free cash flow did Sionna Therapeutics, Inc. generate in fiscal 2025?

Cash from operations of $66.3M minus capital expenditures of $377.0K left free cash flow of -$66.7M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Sionna Therapeutics, Inc.